Remedy Plan Therapeutics
Remedy Plan Therapeutics is a clinical-stage biotech company focused on developing NAMPT inhibitors for patients with acute leukemias and solid tumors. Our mission is to solve a decades-old medical-science puzzle: targeting NAD synthesis in cancer cells without damaging healthy cells. Our lead asset, RPT1G, is a novel, small-molecule NAMPT inhibitor designed for this purpose. Our team comprises experienced scientists, clinicians, and drug developers working together to bring hope to communities affected by these diseases. For more information on Remedy Plan, visit remedyplan.com and follow us on LinkedIn.